Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of LPH-5 in Healthy Participants
NCT06722820Phase 1Not yet recruiting
- Sponsor
- Lophora
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, double-blind trial of LPH-5 in major depressive disorder (MDD) and treatment-resistant depression (TRD) (6 cohorts), sponsored by Lophora. Primary endpoints: Incidence and severity of adverse events (AEs), Incidence of laboratory abnormalities and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
LPH-5
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06722820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722820.